Core Technology - The Z-ProcessTM
CrossCart’s Z-Process is a proprietary multi-step process that solves the rejection response caused by anti-Gal and anti-non gal antibodies, thus enabling the use of porcine and other animal tissue in humans.
Currently, the major obstacle
preventing the transplantation of animal tissue into humans is rejection
of the tissue by the human immune system.
CrossCart has developed proprietary technology that overcomes this
obstacle. The primary cause
of tissue rejection has been identified as a cell and matrix surface
carbohydrate antigen called the alphagalactosyl epitope (a-Gal).
a-Gal
antigen present on the animal tissue is recognized as foreign by the human
immune system, and the tissue is attacked and degraded.
CrossCart’s core technology is a series of tissue treatments that
greatly reduce the presence of a-Gal
epitope in de-vitalized porcine tissue, thereby attenuating the immune
rejection of implanted porcine tissue.
The main component of this proprietary tissue treatment is an
enzyme that effectively alters the structure of the a-Gal
antigen so that it is no longer recognizable by the human immune system.
Secondary causes of tissue rejection have to do with immunological recognition of tissue-specific antigens. CrossCart has developed additional proprietary tissue treatments that attenuate immune responses to these tissue specific antigens as well. Furthermore, CrossCart has developed treatments responsible for encouraging normal healing and integration of implanted tissue into the human body. CrossCart has branded its technology for treating animal tissue the Z-ProcessTM.
The Z-ProcessTM
The Z-Process can be applied towards a variety of
medical purposes. Many medical
procedures require the implantation of tissues, the source of which can be
either from tissue donors (allograft) or the patient’s own body (autograft).
Our core technology can potentially provide an alternative animal
tissue source for many of these procedures.
In cases where an animal tissue source already exists,
CrossCart’s technology can be used to improve product performance.
Xenograft cartilage, bone, heart valves, and soft tissue repair and
augmentation are just a few examples of potential applications for the
technology.
An extensive intellectual property portfolio protects CrossCart’s technology. Nineteen U.S. patents have been issued and eleven are pending. Applicable international filings also protect CrossCart Inc.’s technology.
Research
Publications and References